← Back to Search

Other

Cohort J2 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to day 92
Awards & highlights

Study Summary

This trial tests a new drug to see how safe and effective it is in healthy Japanese people.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to day 92
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 92 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with Adverse events
Number of participants with ECG abnormalities
Number of participants with clinical laboratory abnormalities
+2 more
Secondary outcome measures
Absolute Bioavailability (F) of BMS-986325
Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Maximum observed serum concentration (Cmax)
+4 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort J3Experimental Treatment2 Interventions
Group II: Cohort J2Experimental Treatment2 Interventions
Group III: Cohort J1Experimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
BMS-986325
2023
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,650 Previous Clinical Trials
4,130,807 Total Patients Enrolled

Media Library

BMS-986325 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05813717 — Phase 1
Healthy Subjects Research Study Groups: Cohort J2, Cohort J3, Cohort J1
Healthy Subjects Clinical Trial 2023: BMS-986325 Highlights & Side Effects. Trial Name: NCT05813717 — Phase 1
BMS-986325 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05813717 — Phase 1
~12 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top